05/02/2024 17:00
Days
Hours
Mins
Secs
Until At the Heart of Cardiovascular Disease Prevention 2024 Begins
Details
This evening dinner symposium will educate physicians, advanced care providers and the broader healthcare team on current guidelines and opinion on the identification of risk factors, prevention measures and treatment options for cardiovascular disease. Registration fees starting at $75.00
Date & Time: Thursday May 2, 2024 | 5:00pm - 8:30pm
Location: Brackett's Crossing Country Club | 17976 Judicial Rd, Lakeville, MN 55044
Meet the Faculty
Agenda
5:00pm-6:00pm | Registration, Buffet Dinner & Exhibits |
6:00pm-6:10pm | Welcome (Elizabeth Tuohy, MD) |
6:10pm-6:40pm | Addressing the Interest in GLP-1 RAs (Michael Miedema, MD, MPH; Carolyn Wambach, PharmD; Susan White, RDN) |
6:40pm-7:00pm | LDL Cholesterol - How Low Should We Go? (Ambareesh Bajpai, MD) |
7:00pm-7:20pm | Lipoprotein(a) and Cardiovascular Disease (Elizabeth Tuohy, MD) |
7:20pm-7:40pm | How Does Marijuana Impact Cardiovascular Health? (Felipe Martignoni, MD) |
7:40pm-8:00pm | Expert Roundtable (Moderated by Elizabeth Tuohy, MD) |
8:00pm-8:30pm | Exhibits |
Accreditation
Allina Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Allina Health designates this live activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is designed to meet the Minnesota Board of Nursing continuing education requirements for 2.0 hours of credit.
Learning Objectives
- Discuss the evidence regarding using GLP-1 agonists in cardiovascular disease risk management.
- Name three considerations for LDL cholesterol lowering treatments.
- Recall current information on the role of LP(a) in cardiovascular disease prevention.
- List the effects of marijuana on cardiac health.
Thank You Exhibitors!
Abbott | Kiniksa Pharmaceuticals |
Alnylam Pharmaceuticals | Lexicon Pharmaceuticals, Inc. |
Amgen | Merck & Co., Inc. |
AstraZeneca | NewAmsterdam Pharma |
AtriCure, Inc. | Novartis |
Boehringer-Ingelheim | Novo Nordisk. |
Bristol-Myers Squibb | Pfizer, Inc. |
Edwards Lifesciences | Regeneron |
Esperion Therapeutics | United Therapeutics |
Johnson & Johnson Innovative Medicine |